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ABSTRACT
The purpose of the present study was to assess quality of life (QOL) in n-AMD patients seen in a Malaysian public hospital 
and to further identify visual and demographic factors that may contribute to QOL scores of these patients. Patients 
with any form of n-AMD in at least one eye were recruited from hospital’s ophthalmology department. Bahasa Malaysia 
version of National Eye Institute Visual function questionnaire-25 (NEI-VFQ-25) was administered to all participants. 
Demographics, visual functions (VF) including best corrected distance visual acuity (BCDVA), contrast sensitivity (CS), 
near visual acuity (NVA) and reading speed (RS) were recorded. Eighty-six patients (Malay=26, Indian=23, Chinese=37) 
aged 52 to 85 years, diagnosed with n-AMD were chosen to participate. Their mean NEI-VFQ composite score (NEI-VFQ 
CS) was 66.91 ± 13.07. However, no significant difference in NEI-VFQ CS between gender, races and between the two sub 
groups of n-AMD were observed (p>0.05). NEI-VFQ CS showed a significant association with RS (correlation coefficient 
(ρ) =0.627), NVA (ρ = -.660), BCDVA (ρ = -.586), CS (ρ =.0.515). A linear model showed that a combination of BCDVA, 
NVA, CS is accounted for a significant 38 % variability of NEI-VFQ CS (R2 =0.382, p<0.001). In conclusion, the QOL of 
Malaysian n-AMD patients were found to be low. Thus, the study results indicated the need of developing necessary 
management strategies to address this QOL issues in n-AMD patients in Malaysia. Furthermore, the present study suggested 
incorporating appropriate VF such as near acuity, contrast sensitivity, reading speed in clinical settings while assessing 
n-AMD patients as these VF explain the patient’s perception about the impact of this disease.
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ABSTRAK
Tujuan penyelidikan ini adalah untuk menilai kualiti hidup (QOL) dalam pesakit n-AMD yang mendapat rawatan di hospital 
awam Malaysia dan seterusnya mengenal pasti faktor visual dan demografi yang mungkin menyumbang kepada markah 
QOL bagi pesakit ini. Pesakit yang mempunyai n-AMD pada sekurang-kurangnya satu mata telah diambil daripada jabatan 
oftalmologi hospital. Soal selidik-25 (NEI-VFQ-25) fungsi Institut Visual Mata Nasional versi Bahasa Malaysia diberikan 
kepada semua peserta. Demografi, fungsi visual (VF) termasuk jarak visual ketajaman diperbetulkan terbaik (BCDVA), 
sensitiviti kontra (CS), ketajaman visual dekat (NVA) dan kelajuan bacaan (RS) telah direkodkan. Enam puluh lapan pesakit 
(Melayu = 26, India = 23, Cina = 37) berumur antara 52 dan 85 tahun, didiagnos dengan n-AMD telah memilih untuk 
mengambil bahagian. Min skor komposit NEI-VFQ (NEI-VFQ CS) mereka ialah 66.91 ± 13.07. Walau bagaimanapun, tiada 
perbezaan yang signifikan dalam NEI-VFQ CS antara jantina, kaum dan antara dua kumpulan kecil n-AMD diperhatikan 
(p> 0.05). NEI-VFQ CS menunjukkan hubungan bererti dengan RS (pekali korelasi (ρ) =0.627), NVA (ρ = -.660 ), BCDVA (ρ 
= -.586 ), CS (ρ =.0.515 ). Model linear menunjukkan bahawa gabungan BCDVA, NVA, CS menerangkan perbezaan 38% 
CS NEI-VFQ (R2 = 0.382, p< 0.001) yang ketara. Kesimpulannya, QOL n-AMD pesakit Malaysia didapati adalah rendah. 
Oleh itu, keputusan kajian menunjukkan perlunya keperluan membangunkan strategi pengurusan untuk mengatasi 
isu QOL pada pesakit n-AMD di Malaysia. Selain itu, kajian kini mencadangkan penggabungan VF yang sesuai seperti 
ketajaman dekat, sensitiviti kontra, kelajuan membaca dalam situasi klinikal sambil menilai pesakit n-AMD apabila VF 
ini menerangkan kepada persepsi pesakit tentang kesan penyakit ini. 
Kata kunci: Fungsi visual (VF); neovaskular AMD (n-AMD); Visi sasaran kualiti hidup (VTQOL)
INTRODUCTION
Quality of life (QOL) is a measure of physical, functional, 
psychological and social well-being of an individual. 
Measurement of health related QOL in a diseased population 
provides patient’s perception about the impact of the 
disease and its treatment which is not obtained in testing 
clinical parameters. Thus, in patient-centred model of 
health care, measuring QOL in a diseased individual 
is emphasised more (Centres for Disease Control and 
Prevention 2013; Rebollo & Ortega 2001).
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 Age related macular degeneration (AMD) is one 
of the major causes of blindness in the elderly (WHO 
Visual impairment and blindness 2014). Although AMD 
is thought to be more prevalent in western countries, 
recent researches in Asian countries have reported AMD 
as a major visual concern of aged population (Li et al. 
2008; Mohamad et al. 2017; Oshima et al. 2001; Sanjay 
et al. 2009). It causes central loss of vision affecting the 
person’s ability to perform day to day activities. Several 
researches on AMD have reported that it negatively affects 
the individual’s quality of life restricting many domains of 
life (Berdeaux et al. 2005; Clemons et al. 2003; Hassell et 
al. 2006; Mitchell et al. 2006). However, it has also been 
suggested that investigations on QOL should be measured 
in different types of AMD as treatment types and courses 
varies with the disease type (Taylor et al. 2016; Yuzawa 
et al. 2013). 
 Neovascular AMD (n-AMD) is the most debilitating 
form of AMD causing significant visual impairment. 
Introduction of anti-vascular endothelial growth factor 
(anti-VEGF) in treating n-AMD has reduced the blindness 
caused by this sight threatening condition (Martin et 
al. 2011). However, it requires long term treatment and 
monitoring. Thus, there is a recent trend to evaluate 
the quality of life in n-AMD and its treatment effect 
(Bertelmann et al. 2016; Matamoros et al. 2015; Yuzawa 
et al. 2013). However, there are limited literatures 
available in Asia apart from Singapore eye disease study 
where it is found that both typical Neovascular AMD 
and polypoidal choroidal vasculopathy (PCV), a distinct 
type of Neovascular AMD, possesses noticeable impact 
on the vision related quality of life in Asians (Fenwick 
et al. 2017a). Another study, conducted in Singapore, 
reported that early and late AMD negatively affected the 
vision specific functioning (VSF) in Chinese subjects. 
However, no or comparatively less effect of AMD on 
VSF was found in Indian and Malay subjects living there 
(Fenwick et al. 2017b). Furthermore, a recent research 
suggested demographics of patients receiving anti-VEGF 
treatment including patients with n-AMD, varies from 
region to region (Ziemssen et al. 2017). Thus, it is also 
important to explore impact n-AMD on individuals QOL 
in each population.
 Although QOL has been reported in eye diseases like 
cataract, glaucoma, and diabetic retinopathy in multi-
ethnic Malaysian population (Chandramohan et al. 2017; 
Omar et al. 2014; Rizal et al. 2007), there is no published 
data on QOL in any form of AMD patients in Malaysia. 
Thereby the purpose of this cross sectional observational 
study was to evaluate the vision targeted QOL in n-AMD 
patients in a public hospital of Malaysia and to further 
investigate the demographic and visual factors that 
may be associated with the QOL score in these patients. 
This will enhance our understanding about the patient’s 
perceived impact of n-AMD in Malaysian population 
and will eventually assist in strengthening the existing 
management policy of n-AMD in Malaysia.
MATERIALS AND METHODS
SUBJECTS AND DEMOGRAPHICS
Individuals who are already undergoing anti-VEGF 
treatment or are scheduled for first dose of anti-VEGF 
treatment for any form of neovascular age related macular 
degeneration in at least one eye was recruited between 
December 2016 and August 2017 from a Malaysian 
public hospital for this cross sectional observational study. 
Subgroup classification of n-AMD was done as typical 
n-AMD and AMD with polypoidal choroidal vasculopathy 
(PCV) based on fundus fluorescein angiography (FFA), 
indocyanine green angiography (ICGA) and Optical 
Coherence Tomography (OCT) findings by a senior 
ophthalmologist. Treatment course and type may vary 
between these two subgroups causing different impact on 
QOL. Thereby, they were reported separately. Demographic 
information such as age, gender, race, duration of disease, 
number of injections were recorded.
VISUAL FUNCTIONS
Visual functions including distance and near visual acuity, 
contrast sensitivity and reading speed was evaluated. A 4 
meter ETDRS (Early Treatment Diabetic Retinopathy Study) 
chart was used to measure the best corrected distance visual 
acuity (BCDVA) at 4 meter. If any of the subjects were not 
able to read the top line at 4 meter, the chart was moved 
to 3, 2 and 1 meters until the patient could read the top 
line. Conversion of visual acuity at the particular distance 
was performed. Visual acuity was recorded in logMAR for 
ease of analysis. Near visual acuity (NVA) was measured 
as the threshold print size that was read by the subject with 
best spectacle correction in logMAR using UiTM Malay 
related-word reading chart at a standard distance of 40 cm. 
Contrast sensitivity (CS) was measured using Pelli-Robson 
chart at 1 m. Contrast score based on the contrast of last 
group in which two or three letters were correctly read by 
the subject was recorded. Reading speed (RS) was measured 
using UiTM related-word reading chart in subjects who 
were fluent with Malay. It is a validated Malay language 
reading chart that has been already described earlier 
(Buari et al. 2015). Reading speed was recorded in words 
per min. Reading speed was measured using the method 
recommended by the chart developers (Buari et al. 2015). 
However, in a multi-ethnic study population not all subjects 
could read Malay fluently. Thereby reading speed was not 
measured in all subjects.
NEI-VFQ-25
Vision targeted quality of life using National Eye Health 
Visual function Questionnaire - 25 in Bahasa Malaysia (NEI-
VFQ-25 in BM) (Rahman et al. 2015) was used to measure 
the quality of life. NEI-VFQ was originally developed with 
51 items to assess impact of eye diseases on functional 
activities and well-being of an individual (Mangione et 
al. 1998). Later, a shorter version was developed with 25 
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items and named NEI-VFQ 25 (Mangione et al. 2001). This 
well accepted vision targeted QOL measuring tool has been 
translated and validated in different languages. NEI-VFQ-25 
shows individual’s self-perceived visual function in 11 
different subscales including general health; general vision; 
ocular pain; near activities; distance activities; driving; 
colour vision; peripheral vision and social functioning; role 
difficulties; and dependency. NEI-VFQ is a well-established 
tool for measuring vision targeted quality of life in AMD 
population (Clemons et al. 2003). Furthermore, it has also 
been proved to be a reliable and valid tool to assess QOL 
in patients with AMD (Orr et al. 2011; Revicki et al. 2010). 
Scoring of NEI- VFQ Composite score of NEI-VFQ (NEI-VFQ 
CS) was calculated as per previously described method 
(Broman et al. 2001). The subscale scores were 0-100, 
where a higher NEI-VFQ-25 score indicates better vision 
related quality of life. 
STATISTICAL ANALYSIS
All the data were analysed using SPSS software. Descriptive 
statistics, analysis of variance (ANOVA) and independent 
t-test were employed to compare the NEI-VFQ CS between 
groups. Bi-variate and partial correlation followed by 
multiple regression analysis were done to draw the 
association between the NEI-VFQ CS and visual and 
demographic factors. Although NEI-VFQ CS being the 
dependant variable was normally distributed, many of 
the predicting factors were not normal. For non-normally 
distributed data, a Spearman’s correlation was used. 
Furthermore, a multiple regression test was run to examine 
the relationship between NEI-VFQ score and the visual 
functions including BCDVA, NVA and CS and to find out 
predictor of NEI-VFQ CS. However, reading speed was 
not included as reading speed was measured only in 59 
patients. Thereby, the recommendation of N=50+8K by 
Tabachnick and Fidell (1996) were followed, where N= 
number of cases and K=number of Predictors. 
 Ethics approval was obtained from Medical Research 
Ethics Committee of National Medical Research 
Register (NMRR-16-1965-31826 (IIR)) and Universiti 
Kebangsaan Malaysia Research and Ethics Committee 
(UKM 1.5.3.5/244/NN-186-2014) which follows the tenants 
of Helsinki. Written consent was obtained from all the 
participants. Demographic information including subject’s 
age, gender, ethnicity, duration of disease and number of 
anti-VEGF injections were recorded. 
RESULTS
A total of 86 subjects (47 male and 39 female) with an 
age range of 52 to 85 years (mean age 69.49 ± 8.21 years) 
already undergoing treatment or scheduled for first dose of 
anti-VEGF injection for some form of n-AMD were recruited 
for the study. Fifty-one subjects (59.30%) had PCV in at least 
one eye and 56 subjects (60.47%) had some form of AMD 
in the fellow eye. Twelve subjects (14%) were undergoing 
treatment in both eyes. Cataract, glaucoma, high myopia 
were among the other diagnosis of the fellow eye. However, 
in 12 of the fellow eyes, no abnormality was detected. 
 There were 26 Malays (30.23%), 23 Indians (26.74%) 
and 37 Chinese (43.02%) subjects. Fifty-seven subjects 
had undergone 3 or less anti-VEGF injections whereas 29 
subjects had undergone 4 or more anti-VEGF injections. 
Thirty subjects reported history of experiencing some 
form of visual difficulties for less than 6 months whereas 
21 and 35 subjects reported duration of the disease as 6 to 
12 months and more than 12 months, respectively.
VISUAL FUNCTIONS
DVA in the better seeing eye ranged from 1.3 logMAR 
(6/120) to 0 (6/6). Thirty-one subjects (36 %) had VA of 
better than 0.3 logMAR (6/12) in the better seeing eye. 
Fifty subjects (58%) had mild to moderate impairment in 
which the BCDVA in the better seeing eye was 0.3 logMAR 
to better than 1 logMAR (6/12 to 6/36). Only 5 subjects 
(6%) had severe visual impairment in which BCDVA in the 
better seeing eye was 1 or worse (6/60 or worse). NVA as 
measured with Malay related-word reading chart in better 
seeing eye ranged from 1.3 (N40) to 0 (N1) whereas, 
contrast sensitivity ranged from 0.3 log CS to 1.65 log CS. 
Reading speed was measured in 59 subjects (68.60%) only 
as the other 37 subjects (43.02%) were not able to read 
Bahasa Malaysia fluently. The reading speed measured 
ranged from 52 to 212 words per minute.
NEI-VFQ SCORE
The mean (m) NEI-VFQ composite score was 66.91 ± 13.07. 
The most affected subscales were driving (m=59.25±28.86), 
mental health (m=59.28±16.96), role difficulties 
(m=57.42±18.72), dependency (m=66.57±20.20) and near 
activities (m=68.59±16.53). However, peripheral vision 
(m=79.94±19.86), and colour vision (m=89.07±20.74) 
were not much affected by the disease. NEI-VFQ score in 
different domains are shown in Table 1.
ASSOCIATION WITH DEMOGRAPHIC CHARACTERISTICS
None of the demographic characteristics including age, 
gender, race, months of suffering and number of injections 
showed a significant correlation with NEI-VFQ CS (p>.05). 
However, when subjects with 3 or less injections were 
compared with subjects with 4 or more injections, 
subjects with 3 or less injections showed a significantly 
lower NEI-VFQ score. It was also noticed that subjects 
suffering some form of visual difficulties for less than 6 
months had a significantly lower NE-VFQ CS compared to 
subjects who reported months of suffering as 6 or more 
months. Although, Indians showed a comparatively lower 
QOL score, no significant difference in NEI-VFQ CS were 
observed between the three races. Similarly, there was 
no statistically significant difference found in NEI-VFQ CS 
between typical n-AMD and PCV groups. The mean NEI-VFQ 
scores between different sub groups are shown in Table 2.
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ASSOCIATION WITH VISUAL FUNCTIONS
NEI-VFQ CS showed a significant association (Table 3) with 
RS (ρ=0.627), CS (ρ=0.515), NVA (ρ =-0.660), BCDVA (ρ=-
0.586). When adjusted for age, race, gender and number 
of anti-VEGF injections, this correlation remained (BCDVA 
correlation coefficient (ρ) = -0.559, NVA= -0.636, CS= 
0.517, RS= 0.590). 
 Furthermore, a multiple regression model was set 
with BCDVA, NVA and CS as the predictors. To meet the 
assumptions of multiple regression analysis, severe visual 
impairment, i.e., BCDVA in better eye worse than 1 log MAR 
and/or NVA worse than 1 logMAR and/or CS worse than 0.6 
log CS, (detected as outliers) were excluded from the model. 
This model showed that a combination of these three 
visual functions can be accountable for a significant 38% 
of variance in NEI-VFQ CS, R2=0.382, adjusted R2=0.357, 
TABLE 1. Descriptive statistics of NEI-VFQ (n=86)
Domains Mean ± SD Minimum score Maximum score
NEI-VFQ CS
General health
General vision
Ocular pain
Distance activity
Near activity 
Driving*
Colour vision
Peripheral vision
Mental health
Social Functioning
Role difficulties
Dependency
66.91 ± 13.07
58.14 ± 18.96
55.58 ± 20.67
55.14 ± 16.45
68.86 ± 16.98
68.59 ± 16.53
59.25 ± 28.86
89.07 ± 20.74
79.94 ± 19.86
59.28 ± 16.96
75.74 ± 20.04
57.42 ± 18.72
66.57 ± 20.20
28.33
0.00 
20.00
0.00
16.67
25.00
0.00
10.00
25.00
18.75
 25.00
25.00
16.67
92.20
100.00
100.00
100.00
100.00
100.00
91.67
100.00
100.00
93.75
 100.00
 100.00
 100.00
*n=50; mean ± Standard Deviation (SD)
TABLE 2. Effects of race, number of injection and years of suffering on NEI-VFQ CS 
among Neovascular AMD patients (n=86)
Variables Mean ± SD F / T p-value
Race
  Malay 
  Chinese
  Indian
Type of n-AMD
  Typical n-AMD (n=35)
  PCV (n=51)
 67.69 ± 15.75
68.43 ± 11.56
 63.58 ± 11.98
63.80 ±14.20
68.89 ± 11.86
F=1.043 (2)
T= -2.047 (84)
0.357
0.073
Number of injections
  0 to 3 (n=57)
  4 & above (n=29)
64.73 ± 13.19
71.20 ± 11.93 T= -2.219 (84) 0.029
Months of suffering 
 < 6 months (n=30)
  6 - 12 months (n=21)
 > 12 months (n=35)
62.31 ± 14.24
71.33 ± 8.26
68.19 ± 13.48
F=3.414 (2) 0.038
mean ± Standard Deviation (SD)
TABLE 3. Correlation between the NEI-VFQ and                          
the visual functions
Visual functions Correlation coefficient 
(ρ)
p-value
BCDVAa
NVAa
CSa
RSa (n=59)
-0.586
-0.660
0.515
0.627
0.00
0.00
0.00
0.00
aSpearman’s rho correlation
F (3, 78) =15.255, p=0.00. However, when assessing the 
role of each predictor in the model, it is noted that only 
NVA is a significant predictor of NEI-VFQ CS (Table 4).
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DISCUSSION
Previous researches established that impact of AMD on QOL 
is as fatal as some of the serious health diseases like cancer 
and stroke (Brown et al. 2005). However, the impact may 
vary based on several factors including demographics, 
visual status, family and social support (Fenwick et al. 
2017; Hassell et al. 2006; Matamoros et al. 2015; Sahel 
et al. 2007). This paper is the first to report QOL in n-AMD 
patients undergoing anti-VEGF treatment in a public 
hospital in Malaysia.
 In the present study, subjects with n-AMD showed a 
mean NEI-VFQ CS of 66.9 which is better when compared to 
some of the previous researches. Matamoros et al. (2015) 
reported a mean NEI-VFQ CS of 53.4 in 416 patients suffering 
from active exudates AMD. Another research by Sahel 
et al. (2007) reported a mean NEI-VFQ CS of 52.6 in 360 
patients with wet AMD. The difference between the results 
could be because of the difference in the demographic 
distribution and clinical parameters of the study subjects 
such as visual impairment status, number of injections and 
laterality. In the present study, only 6% of the subjects had 
severe visual impairment whereas 36% of the patients had 
no visual impairment (BCDVA in better seeing eye is better 
than 6/12). However, there was some noticeable effect on 
overall vision targeted QOL score in patients with no visual 
impairment with an average NEI-VFQ CS score of 73.52. 
One of the following reasons might be responsible for this 
finding. Other visual functions such as contrast sensitivity, 
TABLE 4. Unstandardized and standardized regression               
coefficient for regression model
Visual Functions B (95% CI) Beta p-value
BCDVA
NVA
CS
-5.223 -0.586
-27.650 -0.494
3.802 0.074
0.506
0.001
0.524
FIGURE 1. Correlation of NEIVFQ CS with BCDVA (A) and NVA (B)
FIGURE 2. Correlation of NEIVFQ CS with CS (A) and RS (B)
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near vision and reading speed might have been affected in 
some of these subjects though they possessed a near normal 
VA scoring in a high contrast acuity chart that restricted the 
activities related to fine discrimination. In addition, where 
the visual functions of the better seeing eye were normal, 
for example in the eyes without any ocular pathology, visual 
functions in the worse eye might have had some impact on 
the individuals’ activity. Furthermore, psychological well-
being rather than activity limitation might have influenced 
the overall score in some of these patients. Though none 
of the NEI-VFQ can be used to directly diagnose anxiety 
or depression, some of the subscales measure a person’s 
psychological and emotional well-being including mental 
health, role difficulties, dependency, as well as social 
functioning that might have been hampered even in mild 
or no visual impairment. McCloud et al. (2015) reported 
anxiety concerning injections, new limitations to lifestyle, 
uncertainty about treatment being some of the concerns of 
patients with n-AMD undergoing anti-VEGF injections in at 
least one eye. In some of the recent researches, it has been 
shown that patients undergoing treatment of n-AMD are at 
the risk of anxiety, mental stress and depression (Dawson 
et al. 2014) that might impact the overall QOL score despite 
having a near normal visual function. 
 In the present study, there was significant difference 
observed in mean NEI-VFQ CS between bilateral and 
unilateral n-AMD with bilateral n-AMD exhibiting 5.95 
point low mean NEI-VFQ CS compared with unilateral 
ones. Besides, 12 subjects undergoing anti-VEGF treatment 
in both eyes exhibited even lower mean NEI-VFQ CS 
(61.53±11.56). Our result is supported by the recent study 
of Paulus et al. (2017) who have noted significant impact on 
QOL when the fellow eye is affected with n-AMD. Another 
study by Soubrane et al. (2007) reported significantly 
lower NEI-VFQ score in bilateral AMD compared to normal 
subjects. 
 The most affected domains of life in the present study 
were driving, mental health, role difficulties whereas 
peripheral vision and colour vision were some of the 
aspects which remained unaffected or less affected. These 
findings are supported by previous literature (Hassell et al. 
2006; Matamoros et al. 2015). 
 PCV is one of the variant of Asian n-AMD (Nazima et 
al. 2016). However, there are limited literatures on QOL in 
PCV patients. A recent study found that both typical AMD 
and PCV had a detrimental impact on patients QOL using the 
Impact of Visual Impairment (IVI) scale. However, there 
was no significant difference found between these two 
groups (Fenwick et al. 2017a). Similarly, the present study 
comprising 59% of the subjects with PCV in at least one eye 
showed no significant difference in QOL score between PCV 
and typical wet AMD patients. This indicates that although 
treatment pattern varies between two sub groups of wet 
AMD, overall impact of the disease on patients may be 
similar.
 The present study shows that visual functions 
including near visual acuity, reading speed, distance 
visual acuity and contrast sensitivity had significantly 
strong correlation with NEI-VFQ CS. When adjusted for 
the demographic factors, these correlations remained. 
Although reading speed showed strong correlation with 
NEI-VFQ CS, it could not be included into the regression 
model due to small sample size. Therefore, a linear model 
showed combination of BCDVA, NVA, CS is accounted for a 
significant 38% variability of NEI-VFQ CS. Furthermore, the 
regression model showed NVA to be a significant predictor 
of QOL score in subjects with a VA range of 6/6 to 6/60 
in the better seeing eye. This indicates that testing visual 
functions including near vision, reading speed and contrast 
sensitivity should be considered as these visual functions 
are associated with the visual difficulties encountered by 
n-AMD patients and they explain the impact of n-AMD on 
quality of life of the affected individuals. Thus, the present 
study reemphasises the fact that these additional visual 
functions should be included while assessing treatment and 
rehabilitation outcome of n-AMD patients (Sabour-Pickett 
et al. 2013). 
 Although neither duration of disease nor number of 
injections had demonstrated a significant correlation with 
NEI-VFQ CS, but subjects suffering with AMD for less than 6 
months showed a significantly lower NEI-VFQ CS compared 
with those suffering the disease for 6 or more months. 
Probably, adaptation to the disease course and decrease 
level of uncertainty with time improves the overall score 
QOL. Similarly, when comparing NEI-VFQ CS between 3 or 
less injections and more than 4 injections group, the overall 
score was better in the second group. Again this could 
indicate that when the patient understands the process of 
treatment, it may help them to adapt with the condition. 
Similar concepts of understanding the treatment pattern by 
patients undergoing anti-VEGF treatment were discussed by 
McCloud et al. (2015). 
 A recent study, which included Chinese, Malay and 
Indians residing in Singapore concluded that early and 
late AMD affected vision specific function (VSF) of only 
Chinese patients whereas VSF in Malay were affected only 
in late AMD and VSF of Indian patients were not affected by 
any form of AMD (Fenwick et al. 2017b). However, in the 
present study, though Indians exhibited an overall lower 
NEI-VFQ CS score compared with Chinese and Malay, there 
was no significant difference between them. Dissimilarity 
between results of these two studies indicates the need 
of separate data base for each population. On the other 
hand, NEI-VFQ used in the present study address many 
domains of life, some of them being psychological, social 
well-being whereas visual function index-11 measures 
only visual functions. Activities that do not require fine 
discrimination can be performed in mild to moderate 
visual damage. Thus, in individuals where activities that 
require fine discrimination such as reading, fixing things 
at home are not priorities on a regular basis, overall vision 
related functioning may not be hampered, however, in these 
patients, other domains of life including mental health, 
role difficulties and social functioning may get affected 
by the disease reducing the overall vision targeted quality 
of life. Thus, in present study, subjects without any visual 
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impairment (BCDVA 6/12 or better in better seeing eye) 
also showed some impact on NEI-VFQ CS. In short, visual 
need is one of the major factors in VSF but vision targeted 
QOL is not only dependant on visual need. This fact also 
might have some role in the discrepancies between two 
study results.
 Furthermore, socio economic status, standard of 
living, facilities availed from government, social and 
cultural background that may vary across the races between 
countries may contribute to the difference in the impact 
of the disease on QOL. However, these factors were not 
assessed in the present study. This can be considered as one 
of the limitations of the study. In addition to it, increasing 
sample size while comparing three ethnic groups may 
provide better understanding and may further strengthen 
our findings. 
CONCLUSION
Both typical n-AMD and PCV patients seen in a public 
hospital in Malaysia exhibited a low NEI-VFQ score 
irrespective of their racial status. Various domains of 
life such as driving, mental health, role difficulties and 
near activities were affected in these patients. However, 
patients who have had undergone 4 or more injections or 
have had the disease for a duration of 6 or more months 
had shown comparatively better NEI-VFQ CS. Thus an early 
diagnosis and treatment might help the affected individual 
to cope with the disease process. Furthermore, visual 
functions in the better eye including BCDVA, NVA, CS and 
RS were significantly related to NEI-VFQ CS. A combination 
of BCVA, NVA and CS of the better eye have shown the 
efficiency to explain a significant 38% variation in NEI-
VFQ CS in n-AMD patients with VA range of 6/6 to 6/60 
in the better seeing eye. Thus, we suggest incorporating 
appropriate visual functions such as near acuity, contrast 
sensitivity and reading speed and QOL assessment 
in clinical settings while measuring disease impact, 
treatment and rehabilitation outcomes. Furthermore, 
developing necessary management strategies comprising 
counselling, peer group support, low vision rehabilitation 
services, should be considered to address this QOL issues 
in n-AMD patients.
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